TY - JOUR
T1 - Immunotherapy for ovarian cancer
T2 - What's next?
AU - Kandalaft, Lana E.
AU - Powell, Daniel J.
AU - Singh, Nathan
AU - Coukos, George
PY - 2011/3/1
Y1 - 2011/3/1
N2 - In the past decade, we have witnessed important gains in the treatment of ovarian cancer; however, additional advances are required to reduce mortality. With compelling evidence that ovarian cancers are immunogenic tumors, immunotherapy should be further pursued and optimized. The dramatic advances in laboratory and clinical procedures in cellular immunotherapy, along with the development of powerful immunomodulatory antibodies, create new opportunities in ovarian cancer therapeutics. Herein, we review current progress and future prospects in vaccine and adoptive T-cell therapy development as well as immunomodulatory therapy tools available for immediate clinical testing.
AB - In the past decade, we have witnessed important gains in the treatment of ovarian cancer; however, additional advances are required to reduce mortality. With compelling evidence that ovarian cancers are immunogenic tumors, immunotherapy should be further pursued and optimized. The dramatic advances in laboratory and clinical procedures in cellular immunotherapy, along with the development of powerful immunomodulatory antibodies, create new opportunities in ovarian cancer therapeutics. Herein, we review current progress and future prospects in vaccine and adoptive T-cell therapy development as well as immunomodulatory therapy tools available for immediate clinical testing.
UR - http://www.scopus.com/inward/record.url?scp=79952296527&partnerID=8YFLogxK
U2 - 10.1200/JCO.2009.27.2369
DO - 10.1200/JCO.2009.27.2369
M3 - Review article
C2 - 21079136
AN - SCOPUS:79952296527
SN - 0732-183X
VL - 29
SP - 925
EP - 933
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 7
ER -